-
Sector Analysis
KOL Perspectives: Voclosporin Data in Lupus Nephritis
› This KOL Insight briefing focuses on perceptions of voclosporin data in lupus nephritis presented at EULAR 2017
-
Product Insights
Myasthenia Gravis Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H1, 2018" provides an overview of Myasthenia Gravis clinical trials scenario. This report provides top line data relating to the clinical trials on Myasthenia Gravis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Consumer Insights
KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis
› This KOL Insight briefing focuses on KOL opinions of the safety of JAK inhibitors in rheumatoid arthritis (RA)
-
Consumer Insights
KOL Perspectives: Mid-to-Late Stage Pipeline Therapies in Lupus
› This KOL Insight briefing focuses on opinions of mid- to late-stage pipeline therapies in lupus
-
Consumer Insights
KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis
› This KOL Insight briefing focuses on perceptions of IL-6 inhibitors in rheumatoid arthritis (RA)
-
Sector Analysis
Myasthenia Gravis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Myasthenia Gravis (MG) is a relatively rare, acquired, chronic, autoimmune neuromuscular disease caused by an antibody-mediated blockade at the neuromuscular transmission, resulting in skeletal muscle weakness and rapid muscle fatigue. In many adults with MG, the thymus gland remains large. People with the disease typically have clusters of immune cells in their thymus gland and may develop thymomas (tumors of the thymus gland). The myasthenia gravis marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, pricing...
-
Product Insights
Hereditary Angioedema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hereditary Angioedema Clinical Trials Market Report Overview There were a total of 204 hereditary angioedema clinical trials conducted as of January 2023. The hereditary angioedema (hae) (c1 esterase inhibitor [c1-inh] deficiency) clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials...
-
Product Insights
Myasthenia Gravis Disease - Global Clinical Trials Review, H1, 2021
GlobalData's clinical trial report, “Myasthenia Gravis Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Myasthenia Gravis Clinical trials scenario. This report provides top line data relating to the clinical trials on Myasthenia Gravis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also...
-
Product Insights
Sarcoidosis Disease - Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Sarcoidosis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Sarcoidosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Sarcoidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Sector Analysis
Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2029
The rheumatoid arthritis (RA) market is expected to grow from $26.2bn in 2019 to $29.1bn in 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 1.0%. This report discusses that although the RA market is expected to grow during the forecast period, this growth will be stymied by erosion from biosimilars. Rose Joachim, PhD, Senior Immunology Analyst at GlobalData, explains: “Between 2019 and 2029, there will be modest growth in the RA market. Growth will...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.